CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $0, lower than 95% of all stocks globally
- PositionDebt-to-equity is 0×, lower than 95% of its Biotechnology peers (median 0.1×)
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
9.81BUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
1.14xvs all stocks
52-Week Change
50.33%vs all stocks
Market Capitalization
9.81BUSDvs all stocks (USD)
Enterprise Value
8.51BUSDvs all stocks (USD)
Forward P/E
-29.34xvs Biotechnology peers
Price to Book (MRQ)
8.33xvs Biotechnology peers
Enterprise to EBITDA
-20.53xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-22.51%vs Biotechnology peers
Return on Equity (TTM)
-41.19%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Jul 19, 2026Gross Profit (TTM)
0.00USDvs all stocks (USD)
EBITDA (TTM)
0.00USDvs all stocks (USD)
Net Income (TTM)
-450.07MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-312.79MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-180.43MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-414.31MUSDvs all stocks (USD)
Pre-tax Income
-424.79MUSDFY2025 · Dec 31, 2025Income Tax Expense
585.00KUSDFY2025 · Dec 31, 2025Net Income
-425.38MUSDFY2025 · Dec 31, 2025EBIT
-414.31MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-414.31MUSDFY2025 · Dec 31, 2025Research & Development
306.97MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
107.34MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
44.73MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-425.38MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-280.33MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
261.75MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-425.38MUSDFY2025 · Dec 31, 2025Stock-based Compensation
86.50MUSDFY2025 · Dec 31, 2025Other Non-cash Items
44.46MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
24.60MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-10.51MUSDFY2025 · Dec 31, 2025Purchase of Investments
-1.06BUSDFY2025 · Dec 31, 2025Sale of Investments
933.69MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-124.08MUSDFY2025 · Dec 31, 2025Other Financing Charges
-382.00KUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
515.34MUSDFY2025 · Dec 31, 2025Shares Outstanding
78.88MSharesUpdated Jul 19, 2026Float Shares
49.11MSharesUpdated Jul 19, 2026Shares Short
2.91MSharesUpdated Jul 19, 2026Short Ratio
0.5600daysvs all stocks
Short % of Shares Outstanding
6.17%vs all stocks
% Held by Insiders
2.78%vs all stocks
% Held by Institutions
113.30%vs all stocks
Total Cash (MRQ)
1.29BUSDvs all stocks (USD)
Total Cash per Share (MRQ)
16.30USDUpdated Jul 19, 2026Total Debt (MRQ)
0.00USDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.00xvs Biotechnology peers
Current Ratio (MRQ)
16.14xvs Biotechnology peers
Book Value per Share (MRQ)
14.89USDUpdated Jul 19, 2026Total Assets
1.41BUSDvs all stocks (USD)
Total Current Assets
1.39BUSDFY2025 · Dec 31, 2025Total Liabilities
164.37MUSDFY2025 · Dec 31, 2025Total Non-current Assets
20.28MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
73.19MUSDFY2025 · Dec 31, 2025Total Current Liabilities
91.17MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
261.75MUSDFY2025 · Dec 31, 2025Other Short-term Investments
1.11BUSDFY2025 · Dec 31, 2025Accounts Payable
30.16MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
35.00KUSDFY2025 · Dec 31, 2025Common Stock (Book)
8.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-972.43MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
1.25BUSDvs all stocks (USD)
52-Week Low
71.13USDUpdated Jul 19, 202652-Week High
123.99USDUpdated Jul 19, 202652-Week Change
50.33%vs all stocks
Beta
1.14xvs all stocks
50-Day MA
112.22USDUpdated Jul 19, 2026200-Day MA
103.43USDUpdated Jul 19, 2026Avg 10-Day Volume
1.35MSharesUpdated Jul 19, 2026Avg 30-Day Volume
3.95MSharesUpdated Jul 19, 2026Diluted EPS (TTM)
-6.06USDUpdated Jul 19, 2026Other Income / Expense
-55.22MUSDFY2025 · Dec 31, 2025Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Debt-to-equity is 0×, lower than 95% of its Biotechnology peers (median 0.1×)Notable
Debt-to-equity: 0.00Industry median: 0.10Industry P5: 0.00Peers compared: 197
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.60
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 30,274,777.221
Market cap is $9.81B, above the global median of $1.15BNotable
Market cap (USD): 9,808,736,754Global Median: 1,146,734,693.424
Companies that share the same coordination system — how they create, deliver, or capture value.
Asymchem Laboratories (Tianjin) Co., Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
Shanghai Fosun Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Corcept Therapeutics Incorporated
Tier 1ProductionApproval-Gated PipelineRule
Kymera Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Apogee Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Laurus Labs Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Abivax SA
Tier 1ProductionApproval-Gated PipelineRule
Masimo Corporation
Tier 1ProductionApproval-Gated PipelineRuleFlow
Dr. Reddy's Laboratories Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Aurobindo Pharma Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow